Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China.
Front Endocrinol (Lausanne). 2023 Jun 1;14:1172089. doi: 10.3389/fendo.2023.1172089. eCollection 2023.
Diabetes mellitus (DM), one of the most common chronic diseases in China, is a risk factor for SARS-COV-2 infection and poor prognosis of COVID-19. The COVID-19 vaccine is one of the key measures to control the pandemic. However, the actual coverage of COVID-19 vaccination and associated factors remain unclear among DM patients in China. We conducted this study to investigate the COVID-19 vaccine coverage, safety, and perceptions among patients with DM in China.
A cross-sectional study of a sample of 2200 DM patients from 180 tertiary hospitals in China was performed using a questionnaire developed through the Wen Juan Xing survey platform to collect information regarding their coverage, safety, and perceptions of COVID-19 vaccination. A multinomial logistic regression analysis model was performed to determine any independent relationships with COVID-19 vaccination behavior among DM patients.
In total, 1929 (87.7%) DM patients have received at least one dose COVID-19 vaccine, and 271 (12.3%) DM patients were unvaccinated. In addition, 65.2% (n = 1434) were booster vaccinated against COVID-19, while 16.2% (n = 357) were only fully vaccinated and 6.3% (n = 138) were only partially vaccinated. The prevalence of adverse effects after the first dose of vaccine, the second dose of vaccine, and the third dose of vaccine were 6.0%, 6.0%, and 4.3% respectively. Multinomial logistic regression analysis showed that DM patients complicated with immune and inflammatory diseases (partially vaccinated: OR = 0.12; fully vaccinated: OR = 0.11; booster vaccinated: OR = 0.28), diabetic nephropathy (partially vaccinated: OR = 0.23; fully vaccinated: OR = 0.50; booster vaccinated: OR = 0.30), and perceptions on the safety of COVID-19 vaccine (partially vaccinated: OR = 0.44; fully vaccinated: OR = 0.48; booster vaccinated: OR = 0.45) were all associated with the three of vaccination status.
This study showed that higher proportion of COVID-19 vaccine coverage among patients with DM in China. The concern about the safety of the COVID-19 vaccine affected the vaccine behavior in patients with DM. The COVID-19 vaccine was relatively safe for DM patients due to all side effects were self-limiting.
糖尿病（DM）是中国最常见的慢性疾病之一，是 SARS-COV-2 感染和 COVID-19 预后不良的危险因素。COVID-19 疫苗是控制大流行的关键措施之一。然而，在中国，DM 患者 COVID-19 疫苗接种的实际覆盖率及其相关因素尚不清楚。我们进行了这项研究，以调查中国 DM 患者对 COVID-19 疫苗的接种率、安全性和认知。
通过问卷星调查平台开发问卷，对来自中国 180 家三级医院的 2200 名 DM 患者进行横断面研究，收集有关其 COVID-19 疫苗接种覆盖率、安全性和认知的信息。采用多项逻辑回归分析模型确定 DM 患者 COVID-19 疫苗接种行为的任何独立关系。
共有 1929 名（87.7%）DM 患者至少接种了一剂 COVID-19 疫苗，271 名（12.3%）DM 患者未接种疫苗。此外，65.2%（n=1434）的患者接受了 COVID-19 加强针接种，16.2%（n=357）的患者仅完成了两针接种，6.3%（n=138）的患者仅完成了一针接种。第一剂、第二剂和第三剂疫苗接种后的不良反应发生率分别为 6.0%、6.0%和 4.3%。多变量逻辑回归分析显示，合并免疫和炎症性疾病（部分接种：OR=0.12；完全接种：OR=0.11；加强接种：OR=0.28）、糖尿病肾病（部分接种：OR=0.23；完全接种：OR=0.50；加强接种：OR=0.30）和对 COVID-19 疫苗安全性的认知（部分接种：OR=0.44；完全接种：OR=0.48；加强接种：OR=0.45）与三种接种状态均相关。
本研究表明，中国 DM 患者 COVID-19 疫苗接种率较高。对 COVID-19 疫苗安全性的关注影响了 DM 患者的疫苗接种行为。由于所有副作用均为自限性，COVID-19 疫苗对 DM 患者相对安全。
